Maria Teresa Fierro

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Youn H. Kim, M. Bagot, Lauren Pinter‐Brown et al. · The Lancet Oncology · 2018 · 621 citations · Full text

Cutaneous T-cell Lymphoma, Lymphoid Neoplasia, Medicine +6

Prognostic Factors in Primary Cutaneous B-Cell Lymphoma: The Italian Study Group for Cutaneous Lymphomas

Pier Luigi Zinzani, Pietro Quaglino, Nicola Pimpinelli et al. · Journal of Clinical Oncology · 2006 · 228 citations · Full text

The relevance of the CD4+ CD26- subset in the identification of circulating Sézary cells

M.G. Bernengo, Mauro Novelli, Pietro Quaglino et al. · British Journal of Dermatology · 2001 · 199 citations

Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study

Pietro Quaglino, Federica Marenco, Simona Osella‐Abate et al. · Annals of Oncology · 2009 · 182 citations · Full text

Medicine, Melanoma, Pathology +5

Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium

Pietro Quaglino, Milena Maule, H. Miles Prince et al. · Annals of Oncology · 2017 · 134 citations · Full text

Lymphoid Neoplasia, Immunodeficiencies, Global Patterns +6